MedPath

Outcomes Following Phacoemulsification With 1.8 & 2.2mm Incision: Randomized Clinical Trial

Not Applicable
Conditions
Cataract
Interventions
Procedure: Microcoaxial Phacoemulsification
Registration Number
NCT01385878
Lead Sponsor
Iladevi Cataract and IOL Research Center
Brief Summary

Cataract surgical techniques have significantly changed in recent years with the widespread adoption of smaller and smaller clear corneal incisions for phacoemulsification. Microincision surgery has many advantages, including reduced surgically induced astigmatism, faster visual recovery, and reduced intra and postoperative inflammation. Curently, microcoaxial phacoemulsification is being performed through 1.8 as well as 2.2 mm incisions. However, there is still a debate as to which is the best absolute incision size for microcoaxial cataract surgery.

The aim of this study is to evaluate incision stability following microcoaxial phacoemulsification performed through 1.8 and 2.2 mm systems, as well as compare intraoperative performance and postoperative outcomes following microcoaxial phacoemulsification performed through these two incision sizes.

Detailed Description

Cataract surgical techniques have significantly changed in recent years with the widespread adoption of smaller and smaller clear corneal incisions for phacoemulsification. Microincision surgery has many advantages, including reduced surgically induced astigmatism, faster visual recovery, and reduced intra and postoperative inflammation. In the recent times, microcoaxial phacoemulsification has gained popularity. The main advantage of this newer technique is that it uses the same methods as the conventional method but with smaller incisions. Curently, microcoaxial phacoemulsification is being performed through 1.8 as well as 2.2 mm incisions. However, there is still a debate as to which is the best absolute incision size for microcoaxial cataract surgery.

The aim of this study is to evaluate incision stability following microcoaxial phacoemulsification performed through 1.8 and 2.2 mm systems, as well as compare intraoperative performance and postoperative outcomes following microcoaxial phacoemulsification performed through these two incision sizes.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
110
Inclusion Criteria

Uncomplicated age related cataracts, NO grade II III, IV (LOCS III classification)

Exclusion Criteria
  • Ocular comorbidity, glaucoma, uveitis, shallow anterior chamber, maximal pupillary dilatation <6mm, high myopia (axial length > 25mm), previous ocular trauma or surgery, pseudoexfoliation, traumatic cataract, subluxated cataract

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Phacoemulsification with 1.8mm incisionMicrocoaxial PhacoemulsificationMicrocoaxial phacoemulsification was performed using a 1.8mm clear corneal incision
Phacoemulsification with 2.2mm incisiMicrocoaxial PhacoemulsificationMicrocoaxial phacoemulsificaiton will be performed through 2.2mm incision
Primary Outcome Measures
NameTimeMethod
Ingress of Trypan blue from the Ocular Surface into the Anterior ChamberImmediately at the end of surgery

At end of surgery, stromal hydration of all incisions will be performed.0.0125% trypan blue will be instilled on the conjunctival surface.After 2 minutes, the surface will be irrigated with balanced salt solution. 0.1ml aqeous aspirate will be obtained from the anterior chamber.Concentration of trypan blue in the aspirate will be ascertained by UV visible spectrophotometry. Log dilutions of concentration of trypan blue will be used for statistical analysis

Secondary Outcome Measures
NameTimeMethod
Surgically Induced AstigmatismAt baseline and 3 months postoperatively
Corneal Endothelial Cell LossBaseline and 3 months postoperatively
Change in Central Corneal ThicknessBaseline and 1 week
Anterior Chamber InflammationBaseline and 1 month

Trial Locations

Locations (1)

Iladevi Cataract & IOL Research Centre

🇮🇳

Ahmedabad, Gujarat, India

© Copyright 2025. All Rights Reserved by MedPath